RARA and cancer: Both antagonists were very effective against patients’ prostate cancer cells, and the pan-RAR antagonist ablated neurosphere formation by the cancer stem cells of pediatric patients’ primitive neuroectodermal and astrocytoma tumors and killed the cancer stem cells’ progeny [76].